Solengepras

Phase 3: large human trials

An experimental non-dopamine pill being tested as an add-on to reduce "off" time in Parkinson's. A Phase 3 trial is running; whether it helps is not yet known.

• Stage: Phase 3 (ongoing)
• Type: Symptomatic
• Developer: Cerevance
• Target: GPR6 receptor (non-dopaminergic)
• How it works: A once-daily pill that works outside the dopamine system, dialing down a brain receptor (GPR6) involved in movement, in the hope of smoothing out motor symptoms without adding more dopamine.
• Who it's for: People with Parkinson's who have motor fluctuations ("off" time) despite taking levodopa; being tested as an add-on.
• Key trials: NCT06553027
• Last reviewed: 2026-08-07

What it is

Almost all Parkinson's medicines work by boosting or mimicking dopamine, which eventually leads to wearing-off and dyskinesia. Solengepras takes a different route: it blocks a receptor called GPR6 that is active in movement circuits, aiming to improve symptoms through a separate pathway. The hope is a smoother response with fewer dopamine-related complications.

Where it stands

It is being studied in a Phase 3 trial (about 330 people) as an add-on to existing Parkinson's medication, taken once daily at 75 mg or 150 mg versus placebo over 12 weeks. Enrollment has completed and results are expected later; nothing is proven yet.

What the data shows so far

The Phase 3 add-on trial measures change in daily "off" time. Non-dopaminergic approaches to Parkinson's have a mixed track record, and this drug's earlier work is not enough to say it works. The pre-specified Phase 3 results, when reported, are what will matter, not company summaries or subgroup readouts.

What families should know

This is a symptomatic treatment aimed at smoothing out good and bad periods, not a disease-modifier and not a cure. It is experimental, not approved, and its main efficacy read-out is still pending.

Caveats

Not approved and not yet shown to work; pivotal Phase 3 results are still pending. It is an add-on for symptom control, not a treatment that slows the disease. New drug classes often disappoint in Phase 3, so cautious expectations are warranted.

Timeline

Most recent first.

• 2026, Enrollment completed; efficacy results awaited.
• 2024, Phase 3 add-on trial (NCT06553027) begins enrolling.

Sources

• Phase 3 trial on ClinicalTrials.gov

Last reviewed: 2026-08-07. Back to the Parkinson's drug pipeline